Resultaterne viste, at pravastatingruppen 12 måneder efter transplantation havde lavere middel (+ / - SD) kolesterolniveau end kontrolgruppen (193 + 36 mod 248 + 49 mg/ dl, p < 0, 001), mindre hyppig hjerteafstødelse ledsaget af hæmodynamisk kompromittering (3 mod 14 patienter, p = 0, 005), bedre overlevelse (94% mod 78%, p = 0, 025) og lavere forekomst af koronar vaskulopati i transplantatet, bedømt på angiografi og på autopsi (3 mod 10 patienter, p = 0, 049).
Results showed that 12 months after transplantation, the pravastatin group had lower mean (+/ -) SD cholesterol levels than the control group (193 + 36 versus 248 + 49 mg/ dL, p < 0.001), less frequent cardiac rejection accompagnied by haemodynamic compromise (3 versus 14 patients, p= 0.005), better survival (94% versus 78%, p=0.025) and a lower incidence of coronary vasculopathy in the transplant as determined by angiography and by autopsy (3 versus 10 patients, p=0.049).